NCT07102706View on ClinicalTrials.gov

Phase I Trial of GR1803 Injection in Patients With RRMM

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

76

Participants

Timeline

Start Date

May 27, 2022

Primary Completion Date

May 20, 2025

Study Completion Date

May 20, 2025

Conditions
Multiple Myeloma (MM)
Interventions
DRUG

GR1803 injection

weekly dose up to week 24 , biweekly dose from week 24 to week 36, and triweekly dose from week 36 to week 52

Trial Locations (1)

310003

The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou

All Listed Sponsors
lead

Genrix (Shanghai) Biopharmaceutical Co., Ltd.

INDUSTRY